

TABLE OF CONTENTS

Contents	Page No.
Abstract	i-iv
Declaration	
Certificate	
Acknowledgements	v-vi
Table of Contents	vii-xii
List of Tables	xiii-xiv
List of Figures	xv-xviii
List of Symbols and Abbreviations	xix-xxi
CHAPTER-I	
Introduction	1-26
1.1 Introduction	1
1.2 Families of venomous snakes	2
1.3 The global burden of snake envenomation: a neglected tropical disease	3
1.4 Epidemiology of snakebite in India	5
1.5 The Indian RV (<i>Daboia russelii</i>) - a category I medically important snake	7
1.5.1 Systemic classification of RV	7
1.5.2 The distinctive features of RV	7
1.5.3 Habitat, geographic distribution and classification of RV	8
1.5.4 Venom delivery apparatus in RV	9
1.5.5 Pathophysiology and clinical manifestations of RV envenomation	11
1.6 Mass spectrometry - an integral tool in the field of snake venom proteomics and antivenomics	11
1.7 Apyrase, a neglected class of nucleotide hydrolytic enzyme of snake venoms	14
1.8 Gap in the study	15
1.9 Aim and objectives of the present study	15
Bibliography	16
Chapter II	
Review of Literature	27-42
2.1 Proteomic strategies to unveil snake venom composition	27
2.1.1 Gel-based proteomic approach	28
2.2.2 LC-based proteomic approach	28
2.2.3 Combined liquid-chromatographic and gel electrophoresis approach	29
2.2 Quantification of venom toxins	29
2.2.1 Label-free quantification approach	29
2.2.2 Quantification by area under RP-HPLC curve (AUC)	30

TABLE OF CONTENTS

Contents	Page No.
2.3 Immuno profiling of venom antigens	31
2.3.1 Enzyme linked immunosorbent assay (ELISA) and Western blot	31
2.3.2 Antivenomics	31
2.3.3 Neutralization of enzyme activities and pharmacological properties of venom	32
2.4 Russell's viper venom composition - biochemical and proteomic analyses	32
2.4.1 A comparative analysis of RVV from different geographical regions of India	32
2.4.2 Biochemical and pharmacological characterization of eastern India (EI) RVV	33
2.4.3 Proteomic characterization of RVV from different geographical locations of the Indian sub-continent and Myanmar	33
2.4.3.1 Myanmar RVV	33
2.4.3.2 Southern Indian RVV	34
2.4.3.3 Sri Lankan RVV	35
2.4.3.4 Pakistan RVV (captive specimens)	36
2.4.3.5 Pakistan RVV (wild specimens)	37
Bibliography	38

CHAPTER III

Materials and Methods	43-68
3.1 Materials	43
3.1.1 Venoms and antivenoms	43
3.1.2 Chromatographic columns, matrices and other fine chemicals	43
3.2 Methods	44
3.2.1 Proteomic analyses of WI, EI and SI RVV	44
3.2.1.1 Fractionation of WI RVV by gel filtration (GF) followed by anion-exchange (AEX) chromatography	44
3.2.1.2 Fractionation of EI RVV by GF chromatography	45
3.2.1.3 Fractionation of SI RVV by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)	45
3.2.1.4 Matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS) analyses of RVV samples	46
3.2.1.5 In-solution or in-gel trypsin digestion of crude venom or its chromatographic fractions	47
3.2.1.6 Electrospray ionization-liquid chromatography-tandem mass spectrometry (ESI-LC-MS/MS) analysis	47
3.2.1.7 LC-MS/MS data analysis and determination of relative abundance of RVV toxins	48

TABLE OF CONTENTS

Contents	Page No.
3.2.2 Enzymatic activities and pharmacological properties of crude RVV and their fractions	50
3.2.2.1 Assay of protein content	50
3.2.2.2 Assay of enzymatic activities	50
3.2.2.2.1 Phospholipase A ₂ activity	50
3.2.2.2.2 L-amino acid oxidase activity	51
3.2.2.2.3 Protease activity	51
3.2.2.2.4 Esterolytic activity	52
3.2.2.2.5 Phosphodiesterase activity	52
3.2.2.2.6 Nucleotidase activities	52
3.2.2.2.7 Hyaluronidase activity	53
3.2.2.3 Assay of pharmacological properties	53
3.2.2.3.1 Effect on plasma clotting activity	53
3.2.2.3.2 FXa-like activity	54
3.2.2.3.3 Haemolytic activity	54
3.2.2.3.4 Platelet modulation activity	55
3.2.3 Neutralization of enzyme activities and pharmacological properties of RVV	55
3.2.4 Assessment of immunological cross-reactivity of RVV samples against commercial polyvalent (PAV) and/or monovalent (MAV) antivenom	56
3.2.4.1 Enzyme-linked immunosorbent assay (ELISA)	56
3.2.4.2 Immunoblot analysis	56
3.2.5 Second generation antivenomics of RVV samples against commercial PAVs	57
3.2.6 Purification and characterization of a novel apyrase enzyme from WI RVV	58
3.2.6.1 Isolation and purification of RVV apyrase	58
3.2.6.1.1 Fractionation of WI RVV through GF followed by anion-exchange chromatography	58
3.2.6.1.2 Assessment of purity and molecular mass of RVV apyrase	58
3.2.6.1.2.1 RP-HPLC analysis	58
3.2.6.1.2.2 SDS-PAGE analysis	59
3.2.6.1.2.3 MALDI-TOF-MS analysis	59
3.2.6.2 Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis and de novo sequencing for identification of apyrase enzyme	59
3.2.6.3 Biochemical characterization	59
3.2.6.3.1 Catalytic activity and stability of apyrase	59
3.2.6.3.2 Substrate specificity of the apyrase	60
3.2.6.3.3 Effect of metal ions and chemical inhibitors on enzymatic activity of apyrase	60

TABLE OF CONTENTS

Contents	Page No.
3.2.6.3.4 Determination of kinetic parameters of apyrase	61
3.2.6.3.5 Determination of carbohydrate content and glycosylation of apyrase	61
3.2.6.3.6 Determination of interaction between ATP/ADP and apyrase by spectrofluorometric analysis	62
3.2.6.4 Pharmacological characterization	63
3.2.6.4.1 Assessment of haemolytic activity and cytotoxicity of apyrase against MCF-7 cells	63
3.2.6.4.2 Plasma clotting activity of RVV apyrase	63
3.2.6.4.3 Platelet modulation and effect on ADP-induced platelet aggregation by apyrase	64
3.2.6.5 Immunological characterization	64
3.2.6.5.1 Neutralization of enzyme activity of RVV apyrase by commercial PAV and MAV	64
3.2.6.5.2 Immuno cross-reactivity of apyrase towards commercial PAV and MAV	64
3.2.7 Statistical analysis	64
Bibliography	64
CHAPTER IV	69-242
Proteomic and antivenomics analyses of western (WI), eastern (EI), and southern India (SI) RVV samples and correlation of venom composition with <i>in vitro</i> biochemical and pharmacological properties of RVV as well as clinical manifestations of RV envenomation	
4.1 Results	69
4.1.1 Determination of molecular mass of WI, EI, and SI RVV proteins	69
4.1.1.1 One dimensional SDS-PAGE analysis	69
4.1.1.2 MALDI-TOF-MS analysis of WI, EI, and SI RVV samples	70
4.1.2 De-complexation of WI, EI, and SI RVV samples	72
4.1.2.1 Fractionation of WI RVV by gel filtration (GF) followed by anion-exchange (AEX) chromatography	72
4.1.2.2 SDS-PAGE analysis of GF fractions of WI RVV	75
4.1.2.3 Fractionation of EI RVV by GF chromatography	76
4.1.2.4 SDS-PAGE analysis of GF fractions of EI RVVs	76
4.1.2.5 De-complexation of SI RVV by SDS-PAGE	78
4.1.3 Proteomic analysis of WI, EI, and SI RVV samples	78
4.1.3.1 The proteome composition of WI RVV sample	78
4.1.3.2 The proteome composition of EI RVV samples	105

TABLE OF CONTENTS

Contents	Page No.
4.1.3.3 The proteome composition of SI RVV sample	161
4.1.3.4 A comparative analysis of the RVV proteomes from EI, WI, and SI	191
4.1.4 Enzymatic activities of crude and/or GF fractions of WI, EI, and SI RVV samples	193
4.1.5 Some pharmacological properties of WI, EI, and SI RVV samples and their GF fractions	198
4.1.6 Neutralization of enzyme activities and pharmacological properties of WI, EI, and SI RVV samples by commercial PAV manufactured in India	203
4.1.7 Assessment of immunological cross-reactivity of RVV samples against commercial polyvalent (PAV) and/or monovalent (MAV) antivenom by ELISA and immunoblot analysis	208
4.1.7.1 ELISA	208
4.1.7.2 Immunoblot analysis	211
4.1.8 Second generation antivenomics of RVV samples against commercial PAVs to identify partial/least immune recognized proteins of RVV	213
4.2 Discussion	216
4.2.1 Densitometry of SDS-PAGs and its correlation with proteomic data	216
4.2.2 Venom proteome composition of RV from WI, SI, and EI	217
4.2.2.1 Enzyme toxins in RVV	219
4.2.2.2 Non-enzyme toxins in RVV	222
4.2.3 The venom compositions of RV from WI, SI, and EI correlates well with their biochemical properties	223
4.2.4 Pharmacology and clinical manifestations of RV envenomations and their correlation with RVV proteome composition determined by proteomic analysis	225
4.2.5 Potency of commercial polyvalent antivenom in the treatment of RV-envenomed patient in India	227
Bibliography	230
CHAPTER V	243-263
Purification and characterization of a novel apyrase (Ruviapyrase) enzyme from the venom of Russell's Viper (<i>Daboia russelii</i>) of western India (WI) origin	
5.1 Results	243
5.1.1 Purification of an apyrase by multi-dimensional chromatography	243
5.1.1.1 Fractionation of WI RVV through GF followed by anion-exchange chromatography	243
5.1.2 Assessment of purity and molecular mass of RVV apyrase	244

TABLE OF CONTENTS

Contents	Page No.
5.1.2.1 RP-HPLC analysis of purified RVV apyrase	244
5.1.2.2 SDS-PAGE analysis of purified RVV apyrase	244
5.1.2.3 MALDI-TOF-MS analysis of Ruviapyrase	246
5.1.3 Mass spectrometry identification of Ruviapyrase	247
5.1.4 Biochemical characterization	247
5.1.4.1 Catalytic activity and stability of Ruviapyrase	247
5.1.4.2 Substrate specificity of Ruviapyrase	250
5.1.4.3 Effect of metal ions and chemical inhibitors on enzymatic activity of Ruviapyrase	251
5.1.4.4 Kinetic parameters of Ruviapyrase	252
5.1.4.5 Carbohydrate content and glycosylation of Ruviapyrase	254
5.1.4.6 Spectrofluorometric interaction between ATP/ADP and Ruviapyrase	254
5.1.5 Pharmacological characterization	256
5.1.5.1 Assessment of cytotoxicity of Ruviapyrase on MCF-7 cells and erythrocytes	256
5.1.5.2 Plasma clotting activity, platelet modulation and effect on ADP-induced platelet aggregation by Ruviapyrase	257
5.1.6 Immunological characterization	257
5.1.6.1 Neutralization of enzyme activity of Ruviapyrase by commercial Indian PAV and MAV	257
5.1.6.2 Immuno cross-reactivity of Ruviapyrase towards commercial PAV and MAV	258
5.2 Discussion	259
Bibliography	261
CHAPTER VI	264-266
Conclusion and future perspectives	
6.1 Conclusion	264
6.2 Future perspectives	265
Publications	267-275
Addendum	276-278